

Does a biological link exist between periodontitis and rheumatoid arthritis?

Rosamma Joseph, MG Jose Raj, Shobha Sundareswaran, Priyanka Chand Kaushik, Amol Vijay Nagrale, Susan Jose, Sreeraj Rajappan

Rosamma Joseph, Priyanka Chand Kaushik, Amol Vijay Nagrale, Sreeraj Rajappan, Department of Periodontics, Government Dental College, Kottayam 686008, Kerala, India

MG Jose Raj, Department of Biochemistry, Government Medical College, Calicut 673008, Kerala, India

Shobha Sundareswaran, Department of Orthodontics, Government Dental College, Calicut 673008, Kerala, India

Susan Jose, Medical College Campus, Calicut 673008, Kerala, India

Author contributions: All authors have contributed to literature search, intellectual content, drafting and editing of the manuscript and language revision; all authors approved the final version to be published.

Correspondence to: Dr. Rosamma Joseph, Professor and Head, Department of Periodontics, Government Dental College, Medical College PO, Calicut 673008, Kerala, India. drrosammajoseph@gmail.com

Telephone: +91-944-6070599 Fax: +91-495-2356781

Received: June 28, 2014 Revised: September 25, 2014

Accepted: October 14, 2014

Published online: November 12, 2014

Citrullination by PAD may act as a putative biologic link between PD and RA. Association of Human leukocytic antigen-DR4 antigen has been established both with RA and PD. Several interleukins and inflammatory mediators (ILs) and Nuclear factor kappa beta ligand are linked to these common chronic inflammatory diseases. Antibodies directed against heat shock protein (hsp 70 ab) of *P. gingivalis*, *P. melanogenicus* and *P. intermedia* are raised in PD as well as RA. Both the conditions share many pathological and immunological similarities. Bacterial infection, genetic susceptibility, altered immune reaction and inflammatory mediators considered responsible for RA are also associated with PD. So it is plausible that a biological link may exist between PD and RA. Therapies aimed at modifying the expression and effect of inflammatory mediators and effector molecules such as matrix metalloproteinases, proinflammatory cytokines and autoantibodies of structural proteins may probably reduce the severity of both RA and PD.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

Abstract

Periodontitis or Periodontal disease (PD) and Rheumatoid arthritis (RA) are two the most common chronic inflammatory diseases. Periodontitis is a biofilm associated destructive inflammatory disease of the periodontium caused by specific microorganisms. Rheumatoid arthritis is an autoimmune condition and is identified by elevated serum autoantibody titre directed against citrullinated peptides or rheumatoid factor. Periodontitis may involve some elements of autoimmunity. Recent studies have established that PD and RA show a common pathway and could be closely associated through a common dysregulation and dysfunction in inflammatory mechanism. The enzyme peptidyl arginine deiminase (PAD), expressed by *Porphyromonas gingivalis* (*P. gingivalis*) is responsible for the enzymatic deimination of arginine residuals to citrulline resulting in protein citrullination and its increased accumulation in RA.

Key words: Periodontal disease; Rheumatoid arthritis; Citrullinated peptidase; *Porphyromonas gingivalis*; Inflammatory marker; Inflammation and autoantibody

Core tip: Periodontal disease (PD) and Rheumatoid arthritis (RA) share many pathological and immunological similarities. Recent studies have established significant association between the two. Bacterial infection, genetic susceptibility, altered immune reaction and inflammatory mediators considered responsible for RA are also associated with PD. So it is plausible that a biological link may exist between PD and RA. Therapies aimed at reduction of inflammatory mediators and effector molecules can probably reduce the severity of both RA and PD.

Joseph R, Jose Raj MG, Sundareswaran S, Kaushik PC, Nagrale AV, Jose S, Rajappan S. Does a biological link exist between periodontitis and rheumatoid arthritis? *World J Rheumatol* 2014; 4(3):

INTRODUCTION

Periodontal disease (PD) is an immuno inflammatory disease of the periodontium which comprises of both hard and soft tissues like gingiva, periodontal ligament, cementum and alveolar bone. It results from a complex interaction between gram negative organisms, their byproducts and the response of the host^[1-4]. The resulting gingival inflammation leads to destruction of both the soft and hard tissues supporting the tooth^[5]. The prevalence is said to be as high as 80% to 90%^[6].

For periodontal tissues in a healthy state, a steady equilibrium exists between tissue destruction and repair. Periodontal destruction is initiated and progressed by specific periodontal microorganisms that colonize in plaque biofilm. Host microbial interaction determines the extent and severity of periodontal disease^[7-9]. A large number of different species of bacteria can be identified in the dental plaque^[10] but only a few of them are implicated in chronic periodontitis^[11,12]. To prevent exacerbated reactions and destruction of host tissues, an appropriate tolerance mechanism is required by the host to recognize and identify nonpathogenic and pathogenic bacteria^[13]. Pattern recognition receptors and microbe associated molecular patterns have a very significant role in periodontal inflammation and adaptive immune response^[13,14].

The equilibrium established between anti-inflammatory and proinflammatory cytokines (IL-1 α , IL-1 β , TNF- α , IL-6^[15], IL-7, IL-11, IL-17A, IL-17F, IFN- γ , IL-4, IL-10, IL-13, IL-16, IFN- α , TGF- β ^[16,17]) is responsible for the net inflammatory response. Increased levels of IL-1 β , IL-12, IL-6, IL-17, TNF- α , and IFN- γ are reported in gingival tissues of chronic destructive periodontitis^[18,19]. In periodontitis both Th1 (IFN- γ , IL-2, TNF- α) and Th2 (IL-4, IL-5, IL-6, IL-13) type cytokines are observed^[20]. There is supporting evidence for the role of IL-17 and Th17 cells in periodontal disease^[21]. IL-17 induces IL-6 and IL-8 secretion by gingival fibroblasts and also up-regulates MMP - Matrix Metalloproteinases (MMP-1) and MMP-3 in these cells^[22,23]. IL-17 also induces IL-1 β and TNF- α secretion from macrophages and gingival epithelial cells^[22,23]. Inflammatory cytokines are produced as a result of activation of toll like receptors of oral epithelial cells by the lipopolysaccharide of the gram negative periodontal pathogens^[24]. Recently it has been reported that pathogenesis of many systemic diseases are associated with these inflammatory mediators. The pathways bridging periodontal infection and systemic health include transient bacteremia via metastatic infection, injury and inflammation resulting from immunological response induced by periodontal pathogens^[25].

Recent studies have demonstrated that chronic periodontitis acts as a risk factor for systemic diseases like diabetes mellitus, cardiovascular disease, adverse pregnancy

outcomes, rheumatoid arthritis etc^[26-28].

Rheumatoid arthritis (RA) is a chronic inflammatory disease of articular joint with unknown etiology marked by a symmetric, peripheral polyarthritis and often results in joint damage and physical disability. The pathogenic hallmark of RA is synovial inflammation and proliferation, focal bone erosion and thinning of articular cartilage. Articular cartilage is an avascular tissue composed of a specialized matrix of collagen, proteoglycans and other proteins. Chondrocytes contribute to the unique cellular component. Cartilage is a highly responsive tissue that reacts to inflammatory mediators and mechanical factors, which in turn alters the balance between cartilage anabolism and catabolism. The structural damage to the mineralized cartilage and subchondral bone is mediated by osteoclasts^[29].

Worldwide prevalence of RA, an autoimmune condition is approximately 1%^[30]. It is diagnosed as chronic inflammatory polyarthritis when five or more joints are affected^[29]. On close observation, a number of similarities seem to exist between the supporting periodontal structures and articular joint (Table 1).

SIMILARITIES BETWEEN RA AND PD

Periodontitis is a destructive chronic inflammatory disease of the periodontium caused by biofilm associated specific microorganisms^[31-33]. Rheumatoid arthritis is an autoimmune condition and is characterized by elevated serum autoantibody titre directed against citrullinated peptides or rheumatoid factor (RF)^[34,35]. Autoantibodies such as RF and anti-citrullinated protein/peptide antibody (ACPA) may be found in the sera of RA patients long before clinical onset of disease^[27]. Periodontitis may also involve some elements of autoimmunity^[36]. Autoantibodies and specific T cells against host molecules, such as type 1 collagen, have been detected in periodontal disease^[23]. Recent studies have established statistically significant association between PD and RA^[37-41]. The likelihood of PD among patients with RA is high. Also a higher prevalence of RA has been reported among patients with moderate to severe PD^[41]. Joseph R. reported more periodontal destruction in RA group, pointing to a positive association between these diseases^[42]. When comparing patients with RA and those with PD, many similarities have been reported in terms of serum cytokine and gene expression profiles, increased levels of serum matrix metalloproteinases, reactive oxygen species, lipid mediators, and neutrophil associated enzymes^[5,43-46]. It has further been proposed that polymorphisms relating to genes encoding inflammatory cytokines might confer susceptibility to RA and PD^[47-49]. Table 2 depicts some similarities observed in the pathogenesis of RA and PD.

Role of *Porphyromonas gingivalis* and immune response

Periodontal pathogens like *Porphyromonas gingivalis* (*P. gingivalis*) can invade the blood vessels and endothelial cells and lead to persistent bacteremia. It has the ability to in-

Table 1 Similarities between periodontal structures and articular joint

Supporting periodontal structures	Articular joint
Periodontal structures comprise of cementum, alveolar bone, periodontal ligament, gingival crevicular fluid and gingiva	Articular joints comprise of articular cartilage, bone, ligaments, synovial cavity, synovial fluid, and synovial capsule
Cementum is an avascular tissue	Articular cartilage is an avascular tissue
Periodontal ligament is a thin connective tissue that surrounds the root connecting it to the alveolar bone	Synovial tissue is a thin layer of connective tissue. It consists primarily of two cell types- type A synoviocytes (macrophage derived) and type B synoviocyte (fibroblast derived)
Periodontal ligament is collagenous and consists of epithelial rests of malassez, fibroblasts, osteoblasts and ground substances (hyaluronic acid and proteoglycans-fibronectin and laminin)	Synovial fibroblasts are the most abundant and produce the structural components of the joints including collagen, fibronectin and laminin
Gingival crevicular fluid is an infiltrate of blood	Synovial fluid is an infiltrate of blood

Table 2 Similarities in pathogenesis periodontal disease and rheumatoid arthritis

PD	RA
Chronic immunoinflammatory disease	Chronic immunoinflammatory disease
Periodontal pathogen is the main etiological agent with some element of autoimmunity	Bacteria/peptide as an adjunct antigen in autoantibody production
HLA-DR antigen association	HLA-DR antigen association
Inflammatory infiltrate mainly consists of B cells, plasma cells, PMN, T cell, dendritic cell, and macrophages	Inflammatory infiltrate consists of T cell, B cell, plasma cell, dendritic cell, mast cell, macrophages, and few granulocytes
Increases level of IL-1, TNF- α , PGE2, MMPs, NF- κ B, RANK/RANKL/OPG, osteoclast activation	Increases level of IL-1, TNF- α , PGE2, MMPs NF- κ B, RANK/RANKL/OPG, osteoclast activation
Th1, \uparrow ed Th2 and Th 17	Th1 = Th2 and Th 17
Role of nitric oxide	Role of nitric oxide
Genetic and environmental influences	Genetic and environmental influences
Bacterial DNA of anaerobes and high antibody titres against heat shock protein of <i>P. gingivalis</i> , <i>P. Melanogenicus</i> and <i>P. Intermedia</i> ^[65]	Bacterial DNA of anaerobes and high antibody titres against heat shock protein of <i>P. gingivalis</i> , <i>P. Melanogenicus</i> and <i>P. Intermedia</i> ^[95]

PD: Periodontal disease; RA: Rheumatoid arthritis; IL: Inflammatory mediator; MMPs: Matrix metalloproteinases; HLA: Human leukocyte antigen; HLA-DR: Human leucocyte antigen- D related; RANK: Receptor activator of nuclear factor kappa- β ; RANKL: Receptor activator of nuclear factor kappa- β ligand; OPG: Osteoprotegerin; *P. gingivalis*: *Porphyromonas Gingivalis*; *P. intermedia*: *Prevotella intermedia*; *P. melaninogenicus*: *Prevotella melaninogenicus*; TNF: Tumor necrosis factor; NF- κ B: Nuclear factor - kappa β ; IL: Interleukin; PGE2: Prostaglandin E2.

vade primary chondrocytes of knee joints. As a result, cell cycle progression gets delayed, ultimately leading to accelerated apoptosis of these chondrocytes^[50]. The virulence of *P. gingivalis* is mainly associated with its trypsin like proteolytic activity and ability to produce arginine and lysine -specific cysteine endopeptidase like gingipain R and gingipain K respectively^[51]. Gingipain aids in evasion of host defense, tissue destruction and infection^[52,53]. It leads to activation of MMPs (1, 3 and 9) and degradation of host proteins (laminin, fibronectin and collagen)^[54]. Being the only identified bacterium with expression of peptidyl arginine deiminase (PAD), *P. gingivalis* and PAD represent a notable pathogenic element of RA^[55-58]. PAD catalyses the deimination of arginine residuals to citrulline, a form of post-translational protein modification^[59] which leads to an irreversible translation of arginine to citrulline^[56,59]. However one important difference is that PAD expressed by *P. gingivalis* and human PAD are not exactly homologous^[56,59]. It has been reported that in RA there is an increased citrullination of structure proteins^[60]. This probably accounts for the fact that *P. gingivalis* titre significantly correlates with ACPA titre in RA patients^[56,61-65].

GENETIC PROFILE IN PD AND RA

The most potent disease risk gene in RA and PD is the genome on the human leukocytic antigen (HLA) re-

gion^[66]. HLA-DR4 antigen is associated with both RA and PD. This genetic association between these chronic inflammatory conditions also points to the biologic link between them^[65,67-69]. Hitchon and colleagues have reported an association between *P. gingivalis* and the presence of ACPA in a population with predominant RA-predisposing HLA-DRB1 alleles. This gene-environment interaction may contribute to the breaking up of self-tolerance to citrullinated proteins. It could also amplify autoimmune reactions which could predispose to RA^[70].

MARKERS OF INFLAMMATION IN PD AND RA

The synovial fluid of RA patients is rich in proinflammatory cytokines and many interleukins, (IL-1, IL-6, IL-8, IL-15, and IL-17) as well as NF- κ B ligand (RANKL) which can be linked with RA^[71,72]. Similar profile of inflammatory mediators has been identified in chronic periodontitis^[35,73,74]. Elevated serum levels of TNF- α is associated with both these chronic inflammatory diseases^[74,75]. Lipopolysaccharides and other bacterial byproducts stimulate the release of TNF- α and it upregulates the release of prostaglandin E2 (PGE2) and MMPs that stimulate osteoclast activation. These inflammatory processes ultimately lead to bone resorption in both RA and PD^[76].




Figure 1 Hypothetical model of biological link between rheumatoid arthritis and periodontal disease.

ACPA: Anti-citrullinated protein/peptide antibody; CRP: C reactive protein; HLA: Human leukocyte antigen; hsp: Heat shock protein; LPS: Lipopolysaccharide, MMPs: Matrix metalloproteinases; NFκB: Nuclear factor kappa β; OPG: Osteoprotegerin; PD: Periodontal disease; PGE2: Prostaglandin E2; RANK: Receptor activator of nuclear factor kappa β; RANKL: Receptor activator of nuclear factor kappa β ligand; RA: Rheumatoid arthritis; RF: Rheumatoid factor; TNF-α: Tumor necrosis factor alpha; ACPA: Anti-citrullinated protein; RF: Rheumatoid factor; *P. gingivalis*: *Porphyromonas gingivalis*; IL: Interleukin.

EFFECTS OF THERAPY FOR RHEUMATOID ARTHRITIS ON PERIODONTAL DISEASE AND THERAPY FOR PERIODONTAL DISEASE ON RHEUMATOID ARTHRITIS

It has been suggested that treatment of periodontitis in patient with RA improved their response to RA therapy^[77-80]. Treatment of RA with disease modifying anti-rheumatic drugs (DMARDS) improves their periodontal condition due to its host modulatory effect, thus masking the gingival inflammation and actual periodontal destruction^[81-83]. Similarly, reduction in the systemic inflammation by the additional effect of periodontal therapy may also have been masked by DMARDS^[35]. Al-Katma *et al.*^[84] assessed the role of scaling and root planning (SRP) on RA and demonstrated that there was an improvement in RA scores in the test group as compared to the control group. Advances in treatment of RA have identified novel therapeutic targets such as anticytokine therapy. Anti-TNF-α therapy used to control RA may also be beneficial in the management of periodontitis^[85-88]. Ortiz *et al.*^[77] assessed the additional effect of non-surgical periodontal therapy (NSPT) in RA patients under anti-TNF-α therapy and reported that regardless of the medications, supportive periodontal therapy had a positive result on the clinical features of RA. In the absence of periodontal treatment anti-TNF-α therapy alone had no relevant outcome on the periodontal condition^[77].

DOES A BIOLOGIC LINK EXIST BETWEEN PERIODONTAL DISEASE AND RHEUMATOID ARTHRITIS?

First of all, PD and RA share many pathological and immunological similarities. A cyclic nature of disease activity is seen in both RA and PD. There is evidence to suggest that PD could act as a potential risk factor for RA^[24,89,90]. Similarly, RA subjects have significantly increased clinical attachment loss (CAL)^[19-21]. Increased levels of antibodies to periodontopathic bacteria are reported to have been identified in sera and synovial tissues of patients with RA^[63,70,81,91]. Correlation of serum level IgG antibodies to *P. gingivalis* with anticyclic citrullinated peptide indicates that serum protein citrullination via peptidyl arginine deiminase of *P. gingivalis* drives RA responses^[63,70]. Citrullination by PAD may act as a biologically plausible mechanistic link between PD and RA. Furthermore the presence of RA might predispose individuals to PD^[92,93]. Clinical trials suggest that treatment of PD has a significant effect on RA severity and vice versa^[84,94].

Second, it is suspected that *IL-1* gene polymorphism affects the cytokine protein in RA and PD. HLA DR4 antigen is associated with both the conditions which points to the biological link between the two^[67].

Third, it is reported that antibodies against heat shock protein (hsp 70 ab) of *P. gingivalis*, *P. melanogenicus* and *P. intermedia* are elevated not only in supporting periodontal tissues but also in synovial tissue of articular joints of RA patients^[91,95].

Fourth point, Both RA and PD have shown raised titres of IL-10, IL-1 α , IL-1 β , MMPs, TNF- α , LT- α and low titres of IL-1 α and IL-6^[45]. A common inflammatory marker dysfunction seems to be associated with both the articular joint and supporting periodontal tissue.

Bacterial infection, genetic susceptibility, altered immune reaction and inflammatory mediators considered responsible for RA are also associated with PD. So it is plausible that a biological link may exist between PD and RA (Figure 1).

EVIDENCES LINKING PD AND RA

Several studies have revealed that the prevalence of PD was high in patients with RA^[40,42] and that PD severity was greater in RA patients^[45]. Mercado *et al*^[39] (2001) demonstrated a relation between RA and severity of periodontitis in a case control clinical study. Pischon *et al*^[40] (2009) in a cross sectional clinical study showed significantly more CAL in RA subjects as compared to non-RA subjects. They have concluded that oral hygiene may account for this association to some extent. Kobayashi *et al*^[49] (2007) reported that IL-1 and FCyR gene polymorphism have potential risk for RA and periodontitis.

Martinez-Martinez *et al*^[96] (2009) in a case series clinical study on subjects with refractory RA and periodontitis found that *P. intermedia*, *P. gingivalis*, and *T. denticola* were the most predominant gram negative bacteria identified in synovial fluid, which substantiates the concept of anti-CCP and citrullinated structure protein. Dissick *et al*^[41] (2010) in a case control study demonstrated that RA+ patients have more moderate to severe periodontitis. They have reported that females and smokers are at more risk in the RA+/periodontitis complex

Okada *et al*^[81] (2011) demonstrated that corticosteroids, anti-rheumatic drugs, NSAIDs and TNF- α antagonists therapy improved the clinical features of periodontitis in RA patients. Presence of anti-PG IgG antibodies in RA+ patients may influence the serum RF level and periodontal health status^[81]. Mayer *et al*^[83] (2009) in a case control study concluded that TNF- α levels correlated with overall CAL and that inhibition of proinflammatory cytokines may account for the reduction of periodontal parameters. In another case control study, Ribeiro *et al*^[94] (2005) evaluated the role of NSPT on RA status and found that RF decreased after periodontal intervention. The effects of NSPT in subjects with and without RA was studied by Pinho Mde *et al*^[97] (2009) and they stated that the relation between RA and periodontal disease activity is unclear. The effect of NSPT on RA patients under anti-TNF- α was studied by Ortiz *et al*^[77] (2009) who inferred that NSPT had a positive effect on the clinical parameters of RA. Okada *et al*^[98] in (2013) suggested that periodontal treatment decreases the levels of antibodies to *P. gingivalis* and citrulline in patients with RA and Periodontitis. They concluded that these observations may reflect the role of *P. gingivalis* in the protein citrullination which is related to the pathogenesis of RA^[98]. Kaur *et al*^[78] (2014) in a systematic review and meta

analysis reported that non surgical periodontal therapy could lead to improvement in clinical and biochemical disease activity in RA.

Quirke *et al*^[99] in 2013 reported that *P. gingivalis* is seemingly distinctive among periodontal pathogens in having PPAD (*P. gingivalis* peptidylarginine deiminase) with potential to evoke autoimmune response. They opined that the peptidyl citrulline specific immune response to PPAD might break tolerance in RA and could be a target for therapy^[99]. Agnihotri *et al*^[100] in (2014) reviewed the link between RA and PD in the elderly and inferred that thorough understanding of the link between the two chronic inflammatory diseases might be beneficial in rendering better health care protection and betterment of the life style of aged individuals.

CONCLUSION

The relationship between RA and PD can be attributed to common dysfunction and dysregulation in inflammatory mechanisms. Apparently, the common factors are bacterial lipopolysaccharides and inflammatory mediators. Development of specific autoantibodies by citrullination of protein by *P. gingivalis* may be the connecting link between RA and PD. Therapies aimed at suppression of inflammatory mediators and effector molecules such as MMP, proinflammatory cytokines and autoantibodies of structural proteins may probably reduce the severity of both RA and PD.

REFERENCES

- 1 Cochran DL. Inflammation and bone loss in periodontal disease. *J Periodontol* 2008; **79**: 1569-1576 [PMID: 18673012 DOI: 10.1902/jop.2008.080233]
- 2 Page RC, Kornman KS. The pathogenesis of human periodontitis: an introduction. *Periodontol 2000* 1997; **14**: 9-11 [PMID: 9567963]
- 3 Offenbacher S. Periodontal diseases: pathogenesis. *Ann Periodontol* 1996; **1**: 821-878 [PMID: 9118282]
- 4 Cantore S, Mirgaldi R, Ballini A, Coscia MF, Scacco S, Papa F, Inchingolo F, Dipalma G, De Vito D. Cytokine gene polymorphisms associate with microbiological agents in periodontal disease: our experience. *Int J Med Sci* 2014; **11**: 674-679 [PMID: 24843315 DOI: 10.7150/ijms.6962]
- 5 Bartold PM, Marshall RI, Haynes DR. Periodontitis and rheumatoid arthritis: a review. *J Periodontol* 2005; **76**: 2066-2074 [PMID: 16277578]
- 6 Saini R, Marawar PP, Shete S, Saini S. Periodontitis, a true infection. *J Glob Infect Dis* 2009; **1**: 149-150 [PMID: 20300407 DOI: 10.4103/0974-777X.56251]
- 7 Kornman KS. Mapping the pathogenesis of periodontitis: a new look. *J Periodontol* 2008; **79**: 1560-1568 [PMID: 18673011 DOI: 10.1902/jop.2008.080213]
- 8 Van Dyke TE. Role of the neutrophil in oral disease: receptor deficiency in leukocytes from patients with juvenile periodontitis. *Rev Infect Dis* 1985; **7**: 419-425 [PMID: 3895356]
- 9 Genco RJ, Van Dyke TE, Levine MJ, Nelson RD, Wilson ME. 1985 Kreshover lecture. Molecular factors influencing neutrophil defects in periodontal disease. *J Dent Res* 1986; **65**: 1379-1391 [PMID: 3023465]
- 10 Paster BJ, Boches SK, Galvin JL, Ericson RE, Lau CN, Levanos VA, Sahasrabudhe A, Dewhirst FE. Bacterial diversity in human subgingival plaque. *J Bacteriol* 2001; **183**: 3770-3783

- [PMID: 11371542]
- 11 **Socransky SS**, Haffajee AD, Cugini MA, Smith C, Kent RL. Microbial complexes in subgingival plaque. *J Clin Periodontol* 1998; **25**: 134-144 [PMID: 9495612]
 - 12 **Socransky SS**, Haffajee AD, Ximenez-Fyvie LA, Ferres M, Mager D. Ecological considerations in the treatment of *Actinobacillus actinomycetemcomitans* and *Porphyromonas gingivalis* periodontal infections. *Periodontol 2000* 1999; **20**: 341-362 [PMID: 10522230]
 - 13 **Beutler B**. Toll-like receptors: how they work and what they do. *Curr Opin Hematol* 2002; **9**: 2-10 [PMID: 11753071]
 - 14 **Beutler B**, Hoebe K, Du X, Ulevitch RJ. How we detect microbes and respond to them: the Toll-like receptors and their transducers. *J Leukoc Biol* 2003; **74**: 479-485 [PMID: 12960260]
 - 15 **Lamster IB**, Novak MJ. Host mediators in gingival crevicular fluid: implications for the pathogenesis of periodontal disease. *Crit Rev Oral Biol Med* 1992; **3**: 31-60 [PMID: 1730070]
 - 16 **Graves DT**, Delima AJ, Assuma R, Amar S, Oates T, Cochran D. Interleukin-1 and tumor necrosis factor antagonists inhibit the progression of inflammatory cell infiltration toward alveolar bone in experimental periodontitis. *J Periodontol* 1998; **69**: 1419-1425 [PMID: 9926773]
 - 17 **Lappin DF**, MacLeod CP, Kerr A, Mitchell T, Kinane DF. Anti-inflammatory cytokine IL-10 and T cell cytokine profile in periodontitis granulation tissue. *Clin Exp Immunol* 2001; **123**: 294-300 [PMID: 11207661]
 - 18 **Górska R**, Gregorek H, Kowalski J, Laskus-Perendyk A, Syczewska M, Madaliński K. Relationship between clinical parameters and cytokine profiles in inflamed gingival tissue and serum samples from patients with chronic periodontitis. *J Clin Periodontol* 2003; **30**: 1046-1052 [PMID: 15002890]
 - 19 **Lester SR**, Bain JL, Johnson RB, Serio FG. Gingival concentrations of interleukin-23 and -17 at healthy sites and at sites of clinical attachment loss. *J Periodontol* 2007; **78**: 1545-1550 [PMID: 17668974]
 - 20 **Matsuki Y**, Yamamoto T, Hara K. Detection of inflammatory cytokine messenger RNA (mRNA)-expressing cells in human inflamed gingiva by combined *in situ* hybridization and immunohistochemistry. *Immunology* 1992; **76**: 42-47 [PMID: 1628899]
 - 21 **Gaffen SL**, Hajishengallis G. A new inflammatory cytokine on the block: re-thinking periodontal disease and the Th1/Th2 paradigm in the context of Th17 cells and IL-17. *J Dent Res* 2008; **87**: 817-828 [PMID: 18719207]
 - 22 **Newman MG**, Takei HH, Klokkevold PR, Carranza FA. Clinical Periodontology 10th ed. New Delhi: Elsevier Science Health Science Division, 2006: 239
 - 23 **Newman MG**, Takei H, Klokkevold PR, Carranza FA. Carranza's Clinical Periodontology 11th edition (Elsevier Health Sciences, 2011: 281-282). Available from: URL: <http://www.clinicalperiodontology.com/>
 - 24 **Tietze K**, Dalpke A, Morath S, Mutters R, Heeg K, Nonnenmacher C. Differences in innate immune responses upon stimulation with gram-positive and gram-negative bacteria. *J Periodontol Res* 2006; **41**: 447-454 [PMID: 16953821]
 - 25 **Akar H**, Akar GC, Carrero JJ, Stenvinkel P, Lindholm B. Systemic consequences of poor oral health in chronic kidney disease patients. *Clin J Am Soc Nephrol* 2011; **6**: 218-226 [PMID: 21115624 DOI: 10.2215/CJN.05470610]
 - 26 **Kuo LC**, Polson AM, Kang T. Associations between periodontal diseases and systemic diseases: a review of the interrelationships and interactions with diabetes, respiratory diseases, cardiovascular diseases and osteoporosis. *Public Health* 2008; **122**: 417-433 [PMID: 18028967]
 - 27 **Löe H**. Periodontal disease. The sixth complication of diabetes mellitus. *Diabetes Care* 1993; **16**: 329-334 [PMID: 8422804]
 - 28 **Mercado F**, Marshall RI, Klestov AC, Bartold PM. Is there a relationship between rheumatoid arthritis and periodontal disease? *J Clin Periodontol* 2000; **27**: 267-272 [PMID: 10783841]
 - 29 **Longo D**, Fauci A, Kasper D, Hauser S, Jameson J. Harrison's Manual of Medicine, 18th ed. New York: McGraw-Hill Education, 2012: 2738
 - 30 **Sacks JJ**, Luo YH, Helmick CG. Prevalence of specific types of arthritis and other rheumatic conditions in the ambulatory health care system in the United States, 2001-2005. *Arthritis Care Res (Hoboken)* 2010; **62**: 460-464 [PMID: 20391499 DOI: 10.1002/acr.20041]
 - 31 **Slots J**, Rams TE. New views on periodontal microbiota in special patient categories. *J Clin Periodontol* 1991; **18**: 411-420 [PMID: 1890221]
 - 32 **Socransky SS**, Haffajee AD. The bacterial etiology of destructive periodontal disease: current concepts. *J Periodontol* 1992; **63**: 322-331 [PMID: 1573546]
 - 33 **Wolff L**, Dahlén G, Aeppli D. Bacteria as risk markers for periodontitis. *J Periodontol* 1994; **65**: 498-510 [PMID: 8046566]
 - 34 **McInnes IB**, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. *Nat Rev Immunol* 2007; **7**: 429-442 [PMID: 17525752]
 - 35 **Rutger Persson G**. Rheumatoid arthritis and periodontitis - inflammatory and infectious connections. Review of the literature. *J Oral Microbiol* 2012; **4** [PMID: 22347541 DOI: 10.3402/jom.v4i0.11829]
 - 36 **Gemmell E**, Yamazaki K, Seymour GJ. The role of T cells in periodontal disease: homeostasis and autoimmunity. *Periodontol 2000* 2007; **43**: 14-40 [PMID: 17214833]
 - 37 **Greenwald RA**, Kirkwood K. Adult periodontitis as a model for rheumatoid arthritis (with emphasis on treatment strategies) *J Rheumatol* 1999; **26**: 1650-1653 [PMID: 10451056]
 - 38 **Käser UR**, Gleissner C, Dehne F, Michel A, Willershausen-Zönnchen B, Bolten WW. Risk for periodontal disease in patients with longstanding rheumatoid arthritis. *Arthritis Rheum* 1997; **40**: 2248-2251 [PMID: 9416864]
 - 39 **Mercado FB**, Marshall RI, Klestov AC, Bartold PM. Relationship between rheumatoid arthritis and periodontitis. *J Periodontol* 2001; **72**: 779-787 [PMID: 11453241]
 - 40 **Pischon N**, Pischon T, Kröger J, Gülmez E, Kleber BM, Bernimoulin JP, Landau H, Brinkmann PG, Schlattmann P, Zernicke J, Buttgeriet F, Detert J. Association among rheumatoid arthritis, oral hygiene, and periodontitis. *J Periodontol* 2008; **79**: 979-986 [PMID: 18533773 DOI: 10.1902/jop.2008.070501]
 - 41 **Dissick A**, Redman RS, Jones M, Rangan BV, Reimold A, Griffiths GR, Mikuls TR, Amdur RL, Richards JS, Kerr GS. Association of periodontitis with rheumatoid arthritis: a pilot study. *J Periodontol* 2010; **81**: 223-230 [PMID: 20151800 DOI: 10.1902/jop.2009.090309]
 - 42 **Joseph R**, Rajappan S, Nath SG, Paul BJ. Association between chronic periodontitis and rheumatoid arthritis: a hospital-based case-control study. *Rheumatol Int* 2013; **33**: 103-109 [PMID: 22228465 DOI: 10.1007/s00296-011-2284-1]
 - 43 **Mercado FB**, Marshall RI, Bartold PM. Inter-relationships between rheumatoid arthritis and periodontal disease. A review. *J Clin Periodontol* 2003; **30**: 761-772 [PMID: 12956651]
 - 44 **de Pablo P**, Chapple IL, Buckley CD, Dietrich T. Periodontitis in systemic rheumatic diseases. *Nat Rev Rheumatol* 2009; **5**: 218-224 [PMID: 19337286 DOI: 10.1038/nrrheum.2009.28]
 - 45 **Havemose-Poulsen A**, Sørensen LK, Stoltze K, Bendtzen K, Holmstrup P. Cytokine profiles in peripheral blood and whole blood cell cultures associated with aggressive periodontitis, juvenile idiopathic arthritis, and rheumatoid arthritis. *J Periodontol* 2005; **76**: 2276-2285 [PMID: 16332240]
 - 46 **Kobayashi T**, Murasawa A, Komatsu Y, Yokoyama T, Ishida K, Abe A, Yamamoto K, Yoshie H. Serum cytokine and periodontal profiles in relation to disease activity of rheumatoid arthritis in Japanese adults. *J Periodontol* 2010; **81**: 650-657 [PMID: 20429644 DOI: 10.1902/jop.2010.090688]
 - 47 **Havemose-Poulsen A**, Sørensen LK, Bendtzen K, Holmstrup P. Polymorphisms within the IL-1 gene cluster: effects on cytokine profiles in peripheral blood and whole blood cell cultures of patients with aggressive periodontitis, juvenile idiopathic arthritis, and rheumatoid arthritis. *J Periodontol* 2007; **78**: 475-492 [PMID: 17335371]
 - 48 **Kobayashi T**, Ito S, Kuroda T, Yamamoto K, Sugita N, Narita I, Sumida T, Gejyo F, Yoshie H. The interleukin-1 and

- Fcgamma receptor gene polymorphisms in Japanese patients with rheumatoid arthritis and periodontitis. *J Periodontol* 2007; **78**: 2311-2318 [PMID: 18052703]
- 49 **Kobayashi T**, Murasawa A, Ito S, Yamamoto K, Komatsu Y, Abe A, Sumida T, Yoshie H. Cytokine gene polymorphisms associated with rheumatoid arthritis and periodontitis in Japanese adults. *J Periodontol* 2009; **80**: 792-799 [PMID: 19405833 DOI: 10.1902/jop.2009.080573]
 - 50 **Pischon N**, Röhner E, Hocke A, N'Guessan P, Müller HC, Matziolis G, Kanitz V, Purucker P, Kleber BM, Bernimoulin JP, Burmester G, Buttgerit F, Detert J. Effects of Porphyromonas gingivalis on cell cycle progression and apoptosis of primary human chondrocytes. *Ann Rheum Dis* 2009; **68**: 1902-1907 [PMID: 19054824 DOI: 10.1136/ard.2008.102392]
 - 51 **Ogrendik M**. Rheumatoid arthritis is linked to oral bacteria: etiological association. *Mod Rheumatol* 2009; **19**: 453-456 [PMID: 19554393 DOI: 10.1007/s10165-009-0194-9]
 - 52 **Imamura T**. The role of gingipains in the pathogenesis of periodontal disease. *J Periodontol* 2003; **74**: 111-118 [PMID: 12593605]
 - 53 **Stathopoulou PG**, Galicia JC, Benakanakere MR, Garcia CA, Potempa J, Kinane DF. Porphyromonas gingivalis induce apoptosis in human gingival epithelial cells through a gingipain-dependent mechanism. *BMC Microbiol* 2009; **9**: 107 [PMID: 19473524 DOI: 10.1186/1471-2180-9-107]
 - 54 **Jie Bao G**, Kari K, Tervahartala T, Sorsa T, Meurman JH. Proteolytic Activities of Oral Bacteria on ProMMP-9 and the Effect of Synthetic Proteinase Inhibitors. *Open Dent J* 2008; **2**: 96-102 [PMID: 19088890 DOI: 10.2174/1874210600802010096]
 - 55 **McGraw WT**, Potempa J, Farley D, Travis J. Purification, characterization, and sequence analysis of a potential virulence factor from Porphyromonas gingivalis, peptidylarginine deiminase. *Infect Immun* 1999; **67**: 3248-3256 [PMID: 10377098]
 - 56 **Rosenstein ED**, Greenwald RA, Kushner LJ, Weissmann G. Hypothesis: the humoral immune response to oral bacteria provides a stimulus for the development of rheumatoid arthritis. *Inflammation* 2004; **28**: 311-318 [PMID: 16245073]
 - 57 **Maresz KJ**, Hellvard A, Sroka A, Adamowicz K, Bielecka E, Koziel J, Gawron K, Mizgalska D, Marcinska KA, Benedyk M, Pyrc K, Quirke AM, Jonsson R, Alzabin S, Venables PJ, Nguyen KA, Mydel P, Potempa J. Porphyromonas gingivalis facilitates the development and progression of destructive arthritis through its unique bacterial peptidylarginine deiminase (PAD). *PLoS Pathog* 2013; **9**: e1003627 [PMID: 24068934 DOI: 10.1371/journal.ppat.1003627]
 - 58 **Abdullah SN**, Farmer EA, Spargo L, Logan R, Gully N. Porphyromonas gingivalis peptidylarginine deiminase substrate specificity. *Anaerobe* 2013; **23**: 102-108 [PMID: 23856045 DOI: 10.1016/j.anaerobe.2013.07.001]
 - 59 **Schellekens GA**, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, van Venrooij WJ. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. *Arthritis Rheum* 2000; **43**: 155-163 [PMID: 10643712]
 - 60 **Wegner N**, Lundberg K, Kinloch A, Fisher B, Malmström V, Feldmann M, Venables PJ. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. *Immunol Rev* 2010; **233**: 34-54 [PMID: 20192991 DOI: 10.1111/j.0105-2896.2009.00850.x]
 - 61 **Haffajee AD**, Socransky SS. Microbial etiological agents of destructive periodontal diseases. *Periodontol* 2000 1994; **5**: 78-111 [PMID: 9673164]
 - 62 **Mikuls TR**, Payne JB, Yu F, Thiele GM, Reynolds RJ, Cannon GW, Markt J, McGowan D, Kerr GS, Redman RS, Reimold A, Griffiths G, Beatty M, Gonzalez SM, Bergman DA, Hamilton BC, Erickson AR, Sokolove J, Robinson WH, Walker C, Chandad F, O'Dell JR. Periodontitis and Porphyromonas gingivalis in patients with rheumatoid arthritis. *Arthritis Rheumatol* 2014; **66**: 1090-1100 [PMID: 24782175 DOI: 10.1002/art.38348]
 - 63 **Mikuls TR**, Payne JB, Reinhardt RA, Thiele GM, Maziarz E, Cannella AC, Holers VM, Kuhn KA, O'Dell JR. Antibody responses to Porphyromonas gingivalis (P. gingivalis) in subjects with rheumatoid arthritis and periodontitis. *Int Immunopharmacol* 2009; **9**: 38-42 [PMID: 18848647 DOI: 10.1016/j.intimp.2008.09.008]
 - 64 **Liao F**, Li Z, Wang Y, Shi B, Gong Z, Cheng X. Porphyromonas gingivalis may play an important role in the pathogenesis of periodontitis-associated rheumatoid arthritis. *Med Hypotheses* 2009; **72**: 732-735 [PMID: 19246161 DOI: 10.1016/j.mehy.2008.12.040]
 - 65 **Mikuls TR**, Thiele GM, Deane KD, Payne JB, O'Dell JR, Yu F, Sayles H, Weisman MH, Gregersen PK, Buckner JH, Keating RM, Derber LA, Robinson WH, Holers VM, Norris JM. Porphyromonas gingivalis and disease-related autoantibodies in individuals at increased risk of rheumatoid arthritis. *Arthritis Rheum* 2012; **64**: 3522-3530 [PMID: 22736291 DOI: 10.1002/art.34595]
 - 66 **Kinloch AJ**, Alzabin S, Brintnell W, Wilson E, Barra L, Wegner N, Bell DA, Cairns E, Venables PJ. Immunization with Porphyromonas gingivalis enolase induces autoimmunity to mammalian α -enolase and arthritis in DR4-IE-transgenic mice. *Arthritis Rheum* 2011; **63**: 3818-3823 [PMID: 21953289 DOI: 10.1002/art.30639]
 - 67 **Marotte H**, Farge P, Gaudin P, Alexandre C, Mougin B, Miossec P. The association between periodontal disease and joint destruction in rheumatoid arthritis extends the link between the HLA-DR shared epitope and severity of bone destruction. *Ann Rheum Dis* 2006; **65**: 905-909 [PMID: 16284099]
 - 68 **Bonfil JJ**, Dillier FL, Mercier P, Reviron D, Foti B, Sambuc R, Brodeur JM, Sedarat C. A "case control" study on the rôle of HLA DR4 in severe periodontitis and rapidly progressive periodontitis. Identification of types and subtypes using molecular biology (PCR-SSO). *J Clin Periodontol* 1999; **26**: 77-84 [PMID: 10048640]
 - 69 **Kapitány A**, Zilahi E, Szántó S, Szűcs G, Szabó Z, Végvári A, Rass P, Sipka S, Szegedi G, Szekanez Z. Association of rheumatoid arthritis with HLA-DR1 and HLA-DR4 in Hungary. *Ann N Y Acad Sci* 2005; **1051**: 263-270 [PMID: 16126967]
 - 70 **Hitchon CA**, Chandad F, Ferucci ED, Willemze A, Ioan-Facsinay A, van der Woude D, Markland J, Robinson D, Elias B, Newkirk M, Toes RM, Huizinga TW, El-Gabalawy HS. Antibodies to porphyromonas gingivalis are associated with anticitrullinated protein antibodies in patients with rheumatoid arthritis and their relatives. *J Rheumatol* 2010; **37**: 1105-1112 [PMID: 20436074 DOI: 10.3899/jrheum.091323]
 - 71 **Astry B**, Harberts E, Moudgil KD. A cytokine-centric view of the pathogenesis and treatment of autoimmune arthritis. *J Interferon Cytokine Res* 2011; **31**: 927-940 [PMID: 22149412 DOI: 10.1089/jir.2011.0094]
 - 72 **Fardellone P**, Séjourné A, Paccou J, Goëb V. Bone remodeling markers in rheumatoid arthritis. *Mediators Inflamm* 2014; **2014**: 484280 [PMID: 24839355 DOI: 10.1155/2014/484280]
 - 73 **Bozkurt FY**, Berker E, Akkuş S, Bulut S. Relationship between interleukin-6 levels in gingival crevicular fluid and periodontal status in patients with rheumatoid arthritis and adult periodontitis. *J Periodontol* 2000; **71**: 1756-1760 [PMID: 11128925]
 - 74 **Cetinkaya B**, Guzeldemir E, Oğus E, Bulut S. Proinflammatory and anti-inflammatory cytokines in gingival crevicular fluid and serum of patients with rheumatoid arthritis and patients with chronic periodontitis. *J Periodontol* 2013; **84**: 84-93 [PMID: 22414257 DOI: 10.1902/jop.2012.110467]
 - 75 **Orita S**, Koshi T, Mitsuka T, Miyagi M, Inoue G, Arai G, Ishikawa T, Hanaoka E, Yamashita K, Yamashita M, Eguchi Y, Toyone T, Takahashi K, Ohtori S. Associations between proinflammatory cytokines in the synovial fluid and radiographic grading and pain-related scores in 47 consecutive patients with osteoarthritis of the knee. *BMC Musculoskelet Disord* 2011; **12**: 144 [PMID: 21714933 DOI: 10.1186/1471-2474-12-144]

- 76 **Xue M**, McKelvey K, Shen K, Minhas N, March L, Park SY, Jackson CJ. Endogenous MMP-9 and not MMP-2 promotes rheumatoid synovial fibroblast survival, inflammation and cartilage degradation. *Rheumatology* (Oxford) 2014 Jun 29; Epub ahead of print [PMID: 24982240]
- 77 **Ortiz P**, Bissada NF, Palomo L, Han YW, Al-Zahrani MS, Panneerselvam A, Askari A. Periodontal therapy reduces the severity of active rheumatoid arthritis in patients treated with or without tumor necrosis factor inhibitors. *J Periodontol* 2009; **80**: 535-540 [PMID: 19335072 DOI: 10.1902/jop.2009.080447]
- 78 **Kaur S**, Bright R, Proudman SM, Bartold PM. Does periodontal treatment influence clinical and biochemical measures for rheumatoid arthritis? A systematic review and meta-analysis. *Semin Arthritis Rheum* 2014 Apr 28; Epub ahead of print [PMID: 24880982 DOI: 10.1016/j.semarthrit.2014.04.009]
- 79 **Monsarrat P**, Vergnes JN, Cantagrel A, Algans N, Cousty S, Kémoun P, Bertrand C, Arrivé E, Bou C, Sédard C, Schaefferbeke T, Nabet C, Sixou M. Effect of periodontal treatment on the clinical parameters of patients with rheumatoid arthritis: study protocol of the randomized, controlled ESPERA trial. *Trials* 2013; **14**: 253 [PMID: 23945051 DOI: 10.1186/1745-6215-14-253]
- 80 **Erciyas K**, Sezer U, Ustün K, Pehlivan Y, Kısacık B, Senyurt SZ, Tarakçıoğlu M, Onat AM. Effects of periodontal therapy on disease activity and systemic inflammation in rheumatoid arthritis patients. *Oral Dis* 2013; **19**: 394-400 [PMID: 22998534 DOI: 10.1111/odi.12017]
- 81 **Okada M**, Kobayashi T, Ito S, Yokoyama T, Komatsu Y, Abe A, Murasawa A, Yoshie H. Antibody responses to periodontopathic bacteria in relation to rheumatoid arthritis in Japanese adults. *J Periodontol* 2011; **82**: 1433-1441 [PMID: 21342003 DOI: 10.1902/jop.2011.110020]
- 82 **Han JY**, Reynolds MA. Effect of anti-rheumatic agents on periodontal parameters and biomarkers of inflammation: a systematic review and meta-analysis. *J Periodontal Implant Sci* 2012; **42**: 3-12 [PMID: 22413068 DOI: 10.5051/jpis.2012.42.1.3]
- 83 **Mayer Y**, Balbir-Gurman A, Machtei EE. Anti-tumor necrosis factor-alpha therapy and periodontal parameters in patients with rheumatoid arthritis. *J Periodontol* 2009; **80**: 1414-1420 [PMID: 19722791 DOI: 10.1902/jop.2009.090015]
- 84 **Al-Katma MK**, Bissada NF, Bordeaux JM, Sue J, Askari AD. Control of periodontal infection reduces the severity of active rheumatoid arthritis. *J Clin Rheumatol* 2007; **13**: 134-137 [PMID: 17551378]
- 85 **Kobayashi T**, Yokoyama T, Ito S, Kobayashi D, Yamagata A, Okada M, Oofusa K, Narita I, Murasawa A, Nakazono K, Yoshie H. Periodontal and Serum Protein Profiles in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitor Adalimumab. *J Periodontol* 2014 May 26; Epub ahead of print [PMID: 24857321]
- 86 **Üstün K**, Erciyas K, Kısacık B, Sezer U, Pehlivan Y, Öztüzcu S, Gündoğar H, Onat AM. Host modulation in rheumatoid arthritis patients with TNF blockers significantly decreases biochemical parameters in periodontitis. *Inflammation* 2013; **36**: 1171-1177 [PMID: 23649513 DOI: 10.1007/s10753-013-9652-9]
- 87 **Queiroz-Junior CM**, Bessoni RL, Costa VV, Souza DG, Teixeira MM, Silva TA. Preventive and therapeutic anti-TNF- α therapy with pentoxifylline decreases arthritis and the associated periodontal co-morbidity in mice. *Life Sci* 2013; **93**: 423-428 [PMID: 23911669 DOI: 10.1016/j.lfs.2013.07.022]
- 88 **Savioli C**, Ribeiro AC, Fabri GM, Calich AL, Carvalho J, Silva CA, Viana VS, Bonfá E, Siqueira JT. Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis. *J Clin Rheumatol* 2012; **18**: 180-184 [PMID: 22647860 DOI: 10.1097/RHU.0b013e31825828be]
- 89 **Scher JU**, Bretz WA, Abramson SB. Periodontal disease and subgingival microbiota as contributors for rheumatoid arthritis pathogenesis: modifiable risk factors? *Curr Opin Rheumatol* 2014; **26**: 424-429 [PMID: 24807405 DOI: 10.1097/BOR.0000000000000076]
- 90 **Scher JU**, Abramson SB. Periodontal disease, Porphyromonas gingivalis, and rheumatoid arthritis: what triggers autoimmunity and clinical disease? *Arthritis Res Ther* 2013; **15**: 122 [PMID: 24229458]
- 91 **Moën K**, Brun JG, Valen M, Skartveit L, Eribe EK, Olsen I, Jonsson R. Synovial inflammation in active rheumatoid arthritis and psoriatic arthritis facilitates trapping of a variety of oral bacterial DNAs. *Clin Exp Rheumatol* 2006; **24**: 656-663 [PMID: 17207381]
- 92 **Ramamurthy NS**, Greenwald RA, Celiker MY, Shi EY. Experimental arthritis in rats induces biomarkers of periodontitis which are ameliorated by gene therapy with tissue inhibitor of matrix metalloproteinases. *J Periodontol* 2005; **76**: 229-233 [PMID: 15974846]
- 93 **Queiroz-Junior CM**, Madeira MF, Coelho FM, Costa VV, Bessoni RL, Sousa LF, Garlet GP, Souza Dda G, Teixeira MM, Silva TA. Experimental arthritis triggers periodontal disease in mice: involvement of TNF- α and the oral Microbiota. *J Immunol* 2011; **187**: 3821-3830 [PMID: 21890656 DOI: 10.4049/jimmunol.1101195]
- 94 **Ribeiro J**, Leão A, Novaes AB. Periodontal infection as a possible severity factor for rheumatoid arthritis. *J Clin Periodontol* 2005; **32**: 412-416 [PMID: 15811060]
- 95 **Modi DK**, Chopra VS, Bhau U. Rheumatoid arthritis and periodontitis: biological links and the emergence of dual purpose therapies. *Indian J Dent Res* 2009; **20**: 86-90 [PMID: 19336867]
- 96 **Martinez-Martinez RE**, Abud-Mendoza C, Patiño-Marin N, Rizo-Rodríguez JC, Little JW, Loyola-Rodríguez JP. Detection of periodontal bacterial DNA in serum and synovial fluid in refractory rheumatoid arthritis patients. *J Clin Periodontol* 2009; **36**: 1004-1010 [PMID: 19929953 DOI: 10.1111/j.1600-051X.2009.01496.x]
- 97 **Pinho Mde N**, Oliveira RD, Novaes AB, Voltarelli JC. Relationship between periodontitis and rheumatoid arthritis and the effect of non-surgical periodontal treatment. *Braz Dent J* 2009; **20**: 355-364 [PMID: 20126902]
- 98 **Okada M**, Kobayashi T, Ito S, Yokoyama T, Abe A, Murasawa A, Yoshie H. Periodontal treatment decreases levels of antibodies to Porphyromonas gingivalis and citrulline in patients with rheumatoid arthritis and periodontitis. *J Periodontol* 2013; **84**: e74-e84 [PMID: 23701010 DOI: 10.1902/jop.2013.130079]
- 99 **Quirke AM**, Lugli EB, Wegner N, Hamilton BC, Charles P, Chowdhury M, Ytterberg AJ, Zubarev RA, Potempa J, Culshaw S, Guo Y, Fisher BA, Thiele G, Mikuls TR, Venables PJ. Heightened immune response to autocitrullinated Porphyromonas gingivalis peptidylarginine deiminase: a potential mechanism for breaching immunologic tolerance in rheumatoid arthritis. *Ann Rheum Dis* 2014; **73**: 263-269 [PMID: 23463691 DOI: 10.1136/annrheumdis-2012-202726]
- 100 **Agnihotri R**, Gaur S. Rheumatoid arthritis in the elderly and its relationship with periodontitis: a review. *Geriatr Gerontol Int* 2014; **14**: 8-22 [PMID: 23530652 DOI: 10.1111/ggi.12062]

P- Reviewer: Ardila CM, Haraszthy V, Kanzaki H

S- Editor: Ji FF **L- Editor:** A **E- Editor:** Wu HL





Published by **Baishideng Publishing Group Inc**

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

Help Desk: <http://www.wjgnet.com/esps/helpdesk.aspx>

<http://www.wjgnet.com>

